Abstract
Cisplatin is among the most important chemotherapeutic agents ever developed. It is a critical component of therapeutic regimens in a broad range of malignancies. However, more than a generation after its clinical introduction, the exact mechanism of cisplatin action on tumor cells is not fully defined. The preponderance of research over the last three decades has focused on cisplatin interactions with nuclear DNA which are felt to lead to apoptotic cell death in sensitive cells.
However, recent data have shown that cisplatin may have important direct interactions with mitochondria which can induce apoptosis and may account for a significant portion of the clinical activity associated with this drug. These direct interactions between cisplatin and mitochondria may have critical implications for our understanding of this class of drugs and the development of new therapeutic agents.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anderson ME (1998) Chem Biol Interact 111–112:1–14
Andrews PA, Albright KD (1992) Cancer Res 52:1895–1901
Andrews PA, Howell SB (1990) Cancer Cells 2:35–43
Andrews PA, Schiefer MA, Murphy MP, Howell SB (1998) Chem Biol Interact 65:51–58
Asakura T, Ohkawa K (2004) Curr Cancer Drug Targets 4:577–590
Athanasiadis I, Vokes EE (1995) Adv Oncol 11:22–29
Banerjee J, Ghosh S (2004) Biochem Biophys Res Commun 323:310–314
Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J, Kirkpatrick A, van GM (2004) N Engl J Med 350:1945–1952
Bier H (1991) Acta Otolaryngol 111:797–806
Bossy-Wetzel E, Newmeyer DD, Green DR (1998) EMBO J 17:37–49
Boswell AP, Moore GR, Williams RJ (1982) Biochem J 201:523–526
Chabner BA, Myers CE (1985) In: DeVita (ed) Cancer—principles and practice of oncology. Lippencott, Philadelphia, pp 287–329
Colell A, Garcia-Ruiz C, Morales A, Ballesta A, Ookhtens M, Rodes J, Kaplowitz N, Fernandez-Checa JC (1997) Hepatology 26:699–708
Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KS, Schultz CJ, Lee N, Fu KK (2004) N Engl J Med 350:1937–1944
Costantini P, Belzacq AS, Vieira HL, Larochette N, de Pablo MA, Zamzami N, Susin SA, Brenner C, Kroemer G (2000) Oncogene 19:307–314
Crul M, van Waardenburg RC, Beijnen JH, Schellens JH (2002) Cancer Treat Rev 28:291–303
Davis W Jr, Ronai Z, Tew KD (2001) J Pharmacol Exp Ther 296:1–6
de Graaf AO, Van Den Heuvel LP, Dijkman HB, de Abreu RA, Birkenkamp KU, de Witte T, Van Der Reijden BA, Smeitink JA, Jansen JH (2004) Exp Cell Res 299:533–540
Decker WK, Craigen WJ (2000) Mol Genet Metab 70:69–74
Devarajan P, Savoca M, Castaneda MP, Park MS, Esteban-Cruciani N, Kalinec G, Kalinec F (2002) Hear Res 174:45.
Eastman A, Barry MA (1992) Cancer Invest 10:229–240
Eastman A (1990) Cancer Cells 2:275–280
Fernandez-Checa JC, Kaplowitz N, Garcia-Ruiz C, Colell A, Miranda M, Mari M, Ardite E, Morales A (1997) Am J Physiol 273:G7–G17
Fuertes MA, Castilla J, Alonso C, Perez JM (2003) Curr Med Chem 10:257–266
Garcia-Ruiz C, Colell A, Morales A, Kaplowitz N, Fernandez-Checa JC (1995) Mol Pharmacol 48:825–834
Garcia-Ruiz C, Colell A, Morales A, Kaplowitz N, Fernandez-Checa JC (1995) Mol Pharmacol 48:825--834.
Gonzalez VM, Fuertes MA, Alonso C, Perez JM (2001) Mol Pharmacol 59:657–663
Goodisman J, Hagrman D, Tacka KA, Souid AK (2006) Cancer Chemother Pharmacol 57:257–267
Gourdier I, Crabbe L, Andreau K, Pau B, Kroemer G (2004) Oncogene 23:7449–7457
Griffith OW, Meister A (1985) Proc Natl Acad Sci USA 82:4668–4672
Hatefi Y (1985) Annu Rev Biochem 54:1015–1069
Head and Neck Contracts Program (1987) Cancer 60:301–311
Hong WK, Lippman SM, Wolf GT (1993) Cancer Res 53:5113
Hong WK, Shapshay SM, Bhutani R, Craft ML, Ucmalkli A, Yamaguchi K, Vaughan CW, Strong MS (1979) Cancer 44:19–25
Hsu YT, Wolter KG, Youle RJ (1997) Proc Natl Acad Sci USA 94:3668
Isonishi S, Saitou M, Yasuda M, Tanaka T (2001) Hum Cell 14:203–210
Ivanov AI, Christodoulou J, Parkinson JA et al (1998) J Biol Chem 12:14721–14230
Jacobs C, Goffinet DR, Goffinet L, Kohler M, Fee WE (1987) Cancer 60:1178
Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, Knight W, Hochster H, Goodnough LT, Mortimer JE, Einhorn LH, Schacter L, Cherng N, Dalton T, Burroughs J, Rozencweig M (1992) J Clin Oncol 10:257–263
Jacobs C, Makuch R (1990) J Clin Oncol 8:838
Jacobs C (1989) J Clin Oncol 7:823
Jeong HG, Cho HJ, Chang IY, Yoon SP, Jeon YJ, Chung MH, You HJ (2002) FEBS Lett 518:129–134
Jiang S, Cai J, Wallace DC, Jones DP (1999) J Biol Chem 274:29905–29911
Kartalou M, Essigmann JM (2001) Mutat Res 478:23–43
Kish JA, Weaver A, Jacobs J et al (1984) Cancer 53:1819–1824
Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD (1997) Science 21:1132–1136
Kluza J, Gallego M, Loyens A, Beauvillain J, Fernandez J, Cuevas C, Marchetti P, Bailly C (2006) Cancer Res 3177–3187
Kokoszka JE, Waymire KG, Levy SE, Sligh JE, Cai J, Jones DP, MacGregor GR, Wallace DC (2004) Nature 42:461–465
Krimmer T, Rapaport D, Ryan MT, Meisinger C, Kassenbrock CK, Blachly-Dyson E, Forte M, Douglas MG, Neupert W, Nargang FE, Pfanner N (2001) J Cell Biol 152:289–300
Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X (1997) Cell 14:479–489
Liang BC, Ullyatt E (1998) Cell Death Differ 5:694–701
Lijuan J, Yu C, Guozi T, Wenxia T (1997) J Inorg Biochem 1:73–77
Losa JH, Cobo CP, Viniegra JG, Sanchez-Arevalo LV, Cajal S, Sanchez-Prieto R (2003) Oncogene 22:3998–4006
Mandal R, Teixeira C, Li XF (2003) Analyst 128:629–634
Martensson J, Meister A (1989) Proc Natl Acad Sci USA 86:471–475
Martensson J, Jain A, Stole E, Frayer W, Auld PA, Meister A (1991) Proc Natl Acad Sci USA 88:9360–9364
Mathews FS (1985) Prog Biophys Mol Biol 45:1–56
Murata T, Hibasami H, Maekawa S, Tagawa T, Nakashima K (1990) Biochem Int 20:949–955
Narita M, Shimizu S, Ito T, Chittenden T, Lutz RJ, Matsuda H, Tsujimoto Y (1998) Proc Natl Acad Sci USA 8:14681–14686
Nicholson DW, Ambereen Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, Munday NA, Raju SM, Smulson ME, Yamin T-T, Yu VL, Miller DK (1995) Nature 6:37–43
Olivero OA, Semino C, Kassim A, Lopez-Larraza DM, Poirier MC (1995) Mutat Res 346:221–230
Park MS, De Leon M, Devarajan P (2002) J Am Soc Nephrol 13:858–865
Park SY, Chang I, Kim JY, Kang SW, Park SH, Singh K et al (2004) J Biol Chem 279:7512–7520
Preston TJ, Abadi A, Wilson L, Singh G (2001) Adv Drug Deliv Rev 49:45–61
Qian W, Nishikawa M, Haque AM, Hirose M, Mashimo M, Sato E, Inoue M (2005) Am J Physiol Cell Physiol 289:C1466–C1475
Rostovtseva TK, Antonsson B, Suzuki M, Youle J, Colombini M, Bezrukov SM (2004) J Biol Chem 279:13575–13583
Rudin CM, Yang Z, Schumaker LM, VanderWeele DJ, Newkirk K, Egorin MJ et al (2003) Cancer Res 63:312–318
Schubert A, Grimm S (2004) Cancer Res 64:85–93
Schwerdt G, Freudinger R, Schuster C, Silbernagl S, Gekle M (2003) Kidney Int 63:1725–1735
Shimizu S, Narita M, Tsujimoto Y (1999) Nature 399:483–487
Singh G, Maniccia-Bozzo E (1990) Cancer Chemother Pharmacol 26:97–100
Song Q, Lees-Miller SP, Kumar S, Zhang Z, Chan DW, Smith GC, Jackson SP, Alnemri ES, Litwack G, Khanna KK, Lavin MF (1996) EMBO J 15:3238–3246
Sorenson CM, Eastman A (1998) Cancer Res 48:6703–6707
Takahashi A, Alnemri ES, Lazebnik YA, Fernandes-Alnemri T, Litwack G, Moir RD, Goldman RD, Poirier GG, Kaufmann SH, Earnshaw WC (1996) PNAS 93:8395–8400
Tan EH, Adelstein DJ, Sazxton JP, Wood BG, Eliachar I, Van Kirk MA, Lavertu P (1997) Cancer Invest 15:422
Tewari M, Quan LT, O’Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS, Dixit VM (1995) Cell 81:801–809
The Department of Veterans Affairs Laryngeal Cancer Study Group (1991) N Engl J Med 324:1685–1690
Tsujimoto Y (2002) Biosci Rep 22:47–58
Vokes EE (1997) Oncology 11:27
Wang P, Song JH, Song DK, Zhang J, Hao C (2006) Cell Signal
Wheeler RH (1990) Chemotherapy of patients with recurrent head and neck cancers. In: Jacobs C (ed) Carcinomas of the head and neck: Evaluation, management. Kluwer Academic, Boston, pp 171–193
Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG, Youle RJ (1997) J Cell Biol 139:1281–1292
Yanez JA, Teng XW, Roupe KA, Fariss MW, Davies NM (2003) J Pharm Pharm Sci 6:308–314
Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP, Wang X (1997) Science 275:1129–1132
Yang Z, Faustino PJ, Andrews PA, Monastra R, Rasmussen AA, Ellison CD et al (2000) Cancer Chemother Pharmacol 46:255–262
Yang Z, Schumaker LM, Egorin MJ, Zuhowski EG, Guo Z, Cullen KJ (2006) Clin Canc Res 12:5871–5825
Yoshida Y, Izumi H, Torigoe T, Ishiguchi H, Itoh H, Kang D, Kohno K (2003) Cancer Res 63:3729–3734
Yuan ZQ, Feldman RI, Sussman GE, Coppola D, Nicosia SV, Cheng JQ (2003) J Biol Chem 278:23432–23440
Zinkewich-Peotti K, Andrews PA (1992) Cancer Res 52:1902–1906
Zou H, Henzel WJ, Liu X, Lutschg A, Wang X (1997) Cell 90:405–413
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cullen, K.J., Yang, Z., Schumaker, L. et al. Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer. J Bioenerg Biomembr 39, 43–50 (2007). https://doi.org/10.1007/s10863-006-9059-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10863-006-9059-5